Q32 Bio Inc.
NASDAQ:QTTBBiotechnology
-$0.22 today
- Market cap
- $255.25M
- Beta
- -0.23
- P/E (TTM)
- 5.4
- EPS (TTM)
- $2.36
Volume 0.26M
Average 0.74M
QTTB Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Q32 Bio Inc.NASDAQ: QTTB
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $90K fell 24.4% year over year, ahead of the -25.1% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +1.9% a year.
Context
- Depreciation & amortization amounted to 0.7% of revenue in FY2025.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -24.4% holds above the trailing-twelve-month pace of -25.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 391K USD
- Year-over-year change
- -19.7%
- 4-year CAGR
- -55.0%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 391K | -19.7% |
| FY2024 | 2024-12-31 | 487K | -2.4% |
| FY2023 | 2023-12-31 | 499K | +34.9% |
| FY2022 | 2022-12-31 | 370K | -96.1% |
| FY2021 | 2021-12-31 | 9.54M | — |
Depreciation & Amortization vs competitors
How QTTB compares with its peers on the latest reported figures
- QTTB's LTM Mar 2026 depreciation & amortization of $362K is the 4th highest of the 5 companies compared; the peer median is $992.5K.
- Its year-over-year change of -25.1% is the 3rd highest of 5, against a peer median of -20.3%.
- Depreciation & amortization amounts to 0.7% of revenue for QTTB, versus a peer median of 2.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $3.08M | -8.1% | -2.2% | — | |
| LTM Mar 2026 | $1.22M | +6.8% | +9.9% | — | |
| LTM Mar 2026 | $767K | -32.5% | +2.8% | 2.1% | |
| LTM Mar 2026 | $362K | -25.1% | +1.9% | 0.7% | |
| LTM Mar 2026 | $0 | -100.0% | — | — | |
| Peer median (excluding QTTB) | $992.5K | -20.3% | +2.8% | 2.1% | |
Competitors are the stored peer set for QTTB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 33.97M | 6.65M | (6.65M) | 0 | 53.74M |
| Cost of Revenue | 9.54M | 2.6M | 499K | 487K | 391K |
| Gross Profit | 24.43M | 6.65M | (6.65M) | (487K) | 53.35M |
| Gross Margin | 71.9% | 100.0% | 100.0% | — | 99.3% |
| Research & Development | 93.09M | 35.81M | 31.73M | 48.14M | 19.16M |
| Selling, General & Admin | 27.29M | 10.06M | 9.88M | 17.47M | 17.68M |
| Operating Expenses | 120.38M | 45.88M | 41.6M | 65.61M | 36.44M |
| Depreciation & Amortization | 9.54M | 370K | 499K | 487K | 391K |
| EBITDA | (86.22M) | (38.86M) | (47.76M) | (45.3M) | 17.29M |
| EBITDA Margin | -253.8% | -584.2% | 718.0% | — | 32.2% |
| Operating Income | (95.95M) | (39.23M) | (48.26M) | (66.1M) | 16.9M |
| Operating Margin | -282.4% | -589.8% | 725.5% | — | 31.5% |
| Interest Income | 185K | 3.23M | 0 | 3.9M | 2.2M |
| Interest Expense | 0 | 0 | 0 | 300K | 1.1M |
| Other Income / Expenses | 185K | (3.52M) | (5.17M) | 18.39M | 12.92M |
| Income Before Tax | (95.76M) | (42.75M) | (53.43M) | (47.71M) | 29.82M |
| Pre-Tax Margin | -281.9% | -642.7% | 803.3% | — | 55.5% |
| Income Tax Expense | 0 | 62K | 318K | 21K | 0 |
| Net Income | (95.76M) | (42.81M) | (53.74M) | (47.73M) | 29.82M |
| Net Margin | -281.9% | -643.6% | 808.0% | — | 55.5% |
| EPS (Basic) | (31.18) | (13.42) | (16.70) | (5.12) | 2.42 |
| EPS (Diluted) | (31.18) | (13.42) | (16.70) | (6.58) | 2.42 |
| Weighted Avg Shares | 3.07M | 3.19M | 3.22M | 12.2M | 12.3M |
| Weighted Avg Shares (Diluted) | 3.07M | 3.19M | 3.22M | 12.2M | 12.31M |
Q32 Bio Inc.
NASDAQ:QTTB
Intrinsic Alpha fair value
Locked
Current Price
$8.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.